Endogenous expression of transforming growth factor β1 inhibits growth and tumorigenicity and enhances fas-mediated apoptosis in a murine high- grade glioma model

Cancer Research

Volumn 58, Issue 2, 1998, Pages 302-309

  Ashley, David M ^a   Kong, Feng M ^a   Bigner, Darell D ^a   Hale, Laura P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; GLIOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; BRAIN NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; DNA FRAGMENTATION; DNA, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; GENETIC VECTORS; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOMA; MALE; MEMBRANE GLYCOPROTEINS; MICE; NEOPLASMS, EXPERIMENTAL; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0031964370     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Fontana, A., Constam, D. B., Frei, K., Malipiero, U., and Pfister, H. W. Modulation of the immune response by transforming growth factor β. Int. Arch. Allergy Appl. Immunol., 99: 1-7, 1992.
2. Johnson, M. D., Jennings, M. T., Gold, L. I., and Moses, H. L. Transforming growth factor-β in neural embryogenesis and neoplasia. Hum. Pathol., 24: 457-462, 1993.
3. Massague, J. The TGF-β family of growth and differentiation factors. Cell, 49: 437-438, 1987.
4. Cheifetz, S., Weatherbee, J. A., Tsang, M. L., Anderson, J. K., Mole, J. E., Lucas, R., and Massague, J. The transforming growth factor-β system, a complex pattern of cross-reactive ligands and receptors. Cell, 48: 409-415, 1987.
5. Massague, J., Andres, J., Attisano, L., Cheifetz S., Lopez-Casillas, F., Ohtsuki, M., and Wrana, J. L. TGF-β receptors. Mol. Reprod. Dev., 32: 99-104, 1992.
6. Moses, H. L., Pietenpol, J. A., Munger, K., Murphy, C. S., and Yang, E. Y. TGF β regulation of epithelial cell proliferation: role of tumor suppressor genes. Princess Takamatsu Symp., 22: 183-195, 1991.
7. Moses, H. L., Yang, E. Y., and Pietenpol, J. A. TGF-β stimulation and inhibition of cell proliferation: new mechanistic insights. Cell, 63: 245-247, 1990.
8. de Martin, R., Haendler, B., Hofer-Warbinek, R., Gaugitsch, H., Wrann, M., Schlusener, H., Seifert, J. M., Bodmer, S., Fontana, A., and Hofer, E. Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-β gene family. EMBO J., 6: 3673-3677, 1987.
9. Gold, L. I., and Korc, M. Expression of transforming growth factor-b1, 2 and 3 MRNA and protein in human cancer. Dig. Surg., 11: 150-156, 1994.
10. Tada, M., and de Tribolet, N. Recent advances in immunobiology of brain tumors. J. Neurooncol., 17: 261-271, 1993.
11. Kurpad, S. N., Wikstrand, C. J., and Bigner, D. D. Immunobiology of malignant astrocytomas. Semin. Oncol., 21: 149-161, 1994.
12. Jaeckle, K. A. Immunotherapy of malignant gliomas. Semin. Oncol., 21: 249-259, 1994.
13. Fontana, A., Bodmer, S., Frei, K., Malipiero, U., and Siepl, C. Expression of TGF-β 2 in human glioblastoma: a role in resistance to immune rejection? CIBA Found. Symp., 157: 232-238, 1991.
14. Weller, M., and Fontana, A. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-β, T-cell apoptosis, and the immune privilege of the brain. Brain Res. Rev., 21: 128-151, 1995.
15. Tada, M., and de Tribolet, N. Recent advances in immunobiology of brain tumors. J. Neurooncol., 17: 261-271, 1993.
16. Fakhrai, H., Dorigo, O., Shawler, D. L., Lin, H., Mercola, D., Black, K. L., Royston, I., and Sobol, R. E. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc. Natl. Acad. Sci. USA, 93: 2909-2914, 1996.
17. Jachimczak, P., Bogdahn, U., Schneider, J., Behl, C., Meixensberger, J., Apfel, R., Dorries, R., Schlingensiepen, K. H., and Brysch, W. The effect of transforming growth factor-β 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J. Neurosurg., 78: 944-951, 1993.
18. Jachimczak, P., Schwulera, U., and Bogdahn, U. In vitro studies of cytokine-mediated interactions between malignant glioma and autologous peripheral blood mononuclear cells. J. Neurosurg., 81: 579-586, 1994.
19. Jachimczak, P., Fabel-Schulte, K., Hessdorfer, B., Brysch, W., Schlingensiepen, K. H., Blesch, A., and Bogdahn, U. Transforming growth factor-β-mediated regulation of human peripheral blood mononuclear cell proliferation as detected with phosphorothioate antisense oligodeoxynucleolides. Cell. Immunol., 165: 125-133, 1995.
20. Jachimczak, P., Hessdorfer, B., Fabel-Schulte, K., Wismeth, C., Brysch, W., Schlingensiepen, K. H., Bauer, A., Blesch, A., and Bogdahn, U. Transforming growth factor-β-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides. Int. J. Cancer, 65: 332-337, 1996.
21. Whelan, H. T., Przybylski, C., Bajic, D. M., and Schmidt, M. H. Intracellular growth factor metabolism in proliferation of a brain tumor cell line. Intracellular growth factors and brain tumor proliferation. J. Neurooncol., 15: 243-250, 1993.
22. Jennings, M. T., Maciunas, R. J., Carver, R., Bascom, C. C., Juneau, P., Misulis, K., and Moses, H. L. TGF β 1 and TGF β 2 are potential growth regulators for low-grade and malignant gliomas in vitro: evidence in support of an autocrine hypothesis. Int. J. Cancer, 49: 129-139, 1991.
23. Paulus, W., Baur, I., Huettner, C., Schmausser, B., Roggendorf, W., Schlingensiepen, K. H., and Brysch, W. Effects of transforming growth factor-β 1 on collagen synthesis, integrin expression, adhesion and invasion of glioma cells. J. Neuropathol. Exp. Neurol., 54: 236-244, 1995.
24. Helseth, E., Unsgaard, G., Dalen, A., and Vik, R. Effects of type β transforming growth factor in combination with retinoic acid or tumor necrosis factor on proliferation of a human glioblastoma cell line and clonogenic cells from freshly resected human brain tumors. Cancer Immunol. Immunother., 26: 273-279, 1988.
25. Marushige, K., and Marushige, Y. Induction of apoptosis by transforming growth factor β 1 in glioma and trigeminal neurinoma cells. Anticancer Res., 14: 2419-2424, 1994.
26. Weller, M., Frei, K., Groscurth, P., Krammer, P. H., Yonekawa, Y., and Fontana, A. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J. Clin. Invest., 94: 954-964, 1994.
27. Sampson, J. H., Ashley, D. M., Archer, G. E., Fuchs, H. E., Dranoff, G., Hale, L. P., and Bigner, D. D. Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. J. Neurosurg., in press, 1998.
28. Serano, R. D., Pegram, C. N., and Bigner, D. D. Tumorigenic cell culture lines from a spontaneous VM/Dk murine astrocytoma (SMA). Acta Neuropathol., 51: 53-64, 1980.
29. Kurtzberg, J., and Hershfield, M. S. Determinants of deoxyadenosine toxicity in hybrids between human T-and B-lymphoblasts as a model for the development of drug resistance in T-cell acute lymphoblastic leukemia. Cancer Res., 45: 1579-1586, 1985.
30. Tucker, M. A., and Gillespie, G. Y. Production of a bioactive high molecular weight transforming growth factor beta-like molecule by human malignant glioma cell lines. Growth Factors, 11: 153-162, 1994.
31. Chang, H. L., Gillett, N., Figari, I., Lopez, A. R., Palladino, M. A., and Derynck, R. Increased transforming growth factor β expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. Cancer Res., 53: 4391-4398, 1993.
32. Batra, S. K., Castelino-Prabhu, S., Wikstrand, C. J., Xiaopei, Z., Humphrey, P. A., Friedman, H. S., and Bigner, D. D. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Diff., 6: 1251-1259, 1995.
33. Ashley, D. M., Sampson, J. A., Archer, G. E., Batra, S. K., Bigner, D. D., and Hale L. P. Protection against CNS tumor challenge by a genetically modified allogeneic cellular vaccine which generates MHC class I-restricted cytotoxic responses against specific tumor-associated antigens. J. Neuroimmunol., in press, 1998.
34. Pilkington, G. J., Darling, J. L., Lantos, P. L., and Thomas, D. G. Cell lines (VMDk) derived from a spontaneous murine astrocytoma. Morphological and immunocytochemical characterization. J. Neurol. Sci., 62: 115-139, 1983.
35. Knott, J. C., Edwards, A. J., Gullan, R. W., Clarke, T. M., and Pilkington, G. A. A human glioma cell line retaining expression of GFAP and gangliosides, recognized by A2B5 and LB1 antibodies, after prolonged passage. Neuropathol. Appl. Neurobiol., 16: 489-500, 1990.
36. Hebert, M. J., Takano, T., Holthofer, H., and Brady, H. R. Sequential morphologic events during apoptosis of human neutrophils. Modulation by lipoxygenase-derived eicosanoids. J. Immunol., 157: 3105-3115, 1996.
37. Holznagel, E., Hofmann-Lehmann, R., Allenspach, K., Huttner, S., Willett, B., Groscurth, P., Niederer, E., and Lutz, H. Flow cytometric detection of activation-induced cell death (apoptosis) in peripheral blood lymphocyte subpopulations from healthy cats. Vet. Immunol. Immunopathol., 52: 1-14, 1996.
38. Shi, B., De Girolami, U., He, J., Wang, S., Lorenzo, A., Busciglio, J., and Gabuzda, D. Apoptosis induced by HIV-1 infection of the central nervous system. J. Clin. Invest., 98: 1979-1990, 1996.
39. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
40. Steiner, M. S., and Barrack, E. R. Transforming growth factor-β 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol. Endocrinol., 6: 15-25, 1992.
41. Arrick, B. A., Lopez, A. R., Elfman, F., Ebner, R., Damsky, C. H., and Derynck, R. Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor β 1. J. Cell Biol., 118: 715-726, 1992.
42. Wu, S., Theodorescu, D., Kerbel, R. S., Wilson, J. K. V., Mulder, K. M., Humphrey, L. E., and Brattain, M. G. TGF-b1 is an autocrine negative growth regulator of human carcinoma FET cells in vivo as revealed by transfection of an antisense vector. J. Cell Biol., 116: 187-196, 1992.